Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma

The Journal of Allergy and Clinical Immunology
I AzizB J Lipworth

Abstract

We have previously found that beta2-adrenoceptor downregulation and bronchodilator desensitization to albuterol occurred at 36 hours after stopping regular treatment with twice daily salmeterol. In this study we have evaluated these same effects with formoterol given once or twice daily on a regular basis. In a randomized, placebo-controlled, double-blind, double-dummy crossover study, 16 subjects with mild-to-moderate stable asthma (mean [SD] age, 32.5 [15.3] years; mean [SD] FEV1, 73.2 [12.1] percent predicted) receiving regular inhaled corticosteroid therapy received 1 week of treatment with formoterol dry powder (24 microg twice daily [8 AM/8 PM]), formoterol (24 microg once daily [8 PM]), or identical placebo. Lymphocyte beta2-adrenoceptor parameters and a dose-response curve to inhaled albuterol (200 to 1600 microg) were evaluated at 36 hours after the last dose of each treatment period. There were no significant differences in the mean values for albuterol dose-response effects among the three treatment regimens. Comparison of maximal bronchodilator responses between treatments (mean and SEM as change from baseline) revealed no significant differences between treatments for FEV1 (0.47 L [0.06 L] for placebo vs 0.48 L [0....Continue Reading

Citations

Feb 3, 2005·Current Allergy and Asthma Reports·Ian Sayers, Ian P Hall
Jan 3, 2001·European Journal of Pharmacology· Maitland-van der Zee AHH G Leufkens
Feb 19, 2002·British Journal of Clinical Pharmacology·A Fenech, Ian P Hall
Sep 27, 2006·Pharmacogenetics and Genomics·Despina G Contopoulos-IoannidisJohn P A Ioannidis
Jun 5, 2003·Postgraduate Medical Journal·R H GreenA J Wardlaw
Mar 11, 2000·American Journal of Respiratory and Critical Care Medicine·A J Sandford, P D Paré
Oct 6, 2001·American Journal of Respiratory and Critical Care Medicine·J C Kips, R A Pauwels
May 10, 2005·American Journal of Respiratory and Critical Care Medicine·Jaap OostendorpHerman Meurs
Aug 25, 2007·Pharmacogenomics·Despina G Contopoulos-IoannidisJohn Pa Ioannidis
Jun 26, 2001·European Journal of Drug Metabolism and Pharmacokinetics·M G DerksC J Van Boxtel
Dec 22, 2010·European Journal of Medical Research·Iwona Poziomkowska-GesickaT Sroczynski
Apr 13, 2005·Respiratory Medicine·Sarah Haney, Robert J Hancox
Oct 13, 2004·Pulmonary Pharmacology & Therapeutics·Girolamo PelaiaSerafino A Marsico
Aug 16, 2016·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Sunny JabbalBrian Lipworth
Apr 16, 2010·The Cochrane Database of Systematic Reviews·Francine M DucharmeToby J Lasserson
Jun 15, 2014·Pharmacological Reviews·Andrea Ahles, Stefan Engelhardt
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Hanneke J van der Woude, René Aalbers
Aug 4, 2015·Expert Opinion on Drug Metabolism & Toxicology·Kathryn Blake, John Lima
Apr 10, 2004·Life Sciences·Kirsten Leineweber, Otto-Erich Brodde

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.